Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

The main clinical and diagnostic characteristics of patients with low back pain and sacroiliac joint diseases (results of the IOLANTA-II study)

https://doi.org/10.14412/2074-2711-2020-4-57-64

Full Text:

Abstract

Objective: to investigate the clinical and diagnostic characteristics of patients with low back pain in the presence of sacroiliac joint (SIJ) disease.

Patients and methods. The investigation design involved three visits: V 1 (inclusion); V 2 (after 7 days), and V 3 (after 3 months); after the screening period, the investigation enrolled 259 patients aged 65.5 [62.5; 69.5] years; of them there were 165 (63.7%) women. At V 1 , according to magnetic resonance imaging findings, the patients were divided into two groups: 1) 157 patients without confirmed SIJ disease; 2) 102 patients with confirmed SIJ disease. During all visits, the investigators made general clinical and neurological examinations and assessed the intensity of pain syndrome according to a visual analogue scale (VAS) for pain in millimeters, a neuropathic pain component according to the DN4 questionnaire, by determining the blood parameters: transforming growth factor-β1 (TGF-β1), interleukin-1β (IL-1β), IL-6, Beta-Crosslaps, the indicator of bone matrix formation procollagen type 1 N-terminal propeptide (P1NP) and by estimating the urinary level of deoxypyridinoline.

Results and discussion. At all visits, Group 2 patients with higher VAS pain scores had a pain history that was statistically significantly longer (p<0.001). The ANOVA analysis showed that the patients in Group 2 had statistically significantly higher values of TGF-β1, IL-1β, IL-6, and bone resorption markers than those in Group 1, which suggests the relationship between pain syndrome and the presence of an inflammatoryresorptive process in patients with SIJ disease.

Conclusion. A high (39.4%) prevalence of SIJ disease was noted in patients over 60 years of age with low back pain. During the follow-up period, there was a decrease in bone resorption markers and cytokines; however, the SIJ disease group showed less pronounced changes with statistically significant differences in all parameters than in the non-SIJ disease group. It is advisable to consider an algorithm for diagnosing a patient over 60 years of age with low back pain, by mandatorily examining his/her SIJ. Treatment policy, including methods for correction with drugs, should be discussed based on the findings.

About the Authors

I. A. Zolotovskaya
Samara State Medical University, Ministry of Health of Russia
Russian Federation

Irina Aleksandrovna Zolotovskaya

89, Chapaevskaya St., Samara 443099



I. L. Davydkin
Samara State Medical University, Ministry of Health of Russia
Russian Federation
89, Chapaevskaya St., Samara 443099


References

1. Longo UG, Loppini M, Denaro L, et al. Rating scales for low back pain. Br Med Bull. 2010;94:81-144. doi: 10.1093/bmb/ldp052

2. Shmagel A, Foley R, Ibrahim H. Epidemiology of chronic low back pain in US adults: data from the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res. 2016;68:1688-94. doi: 10.1002/acr.22890

3. Grol-Prokopczyk H. Sociodemographic disparities in chronic pain, based on 12-year longitudinal data. Pain. 2017;158:313-22. doi: 10.1097/j.pain.0000000000000762

4. Janevic MR, McLaughlin SJ, Heapy AA, et al. Racial and socioeconomic disparities in disabling chronic pain: findings from the health and retirement study. J Pain. 2017;18:1459-67. doi: 10.1016/j.jpain.2017.07.005

5. Akhmetov BKh, Maksimov YuN, Khaybullina DKh, Gubeev BE. Pain in the lower back: the nuances of diagnosis. Prakticheskaya meditsina. 2014;2(78):17-20 (In Russ.).

6. Kotel'nikov GP, Zolotovskaya IA, Davydkin IL, et al. Pathology of the ileosacral joint in elderly patients with pain in the lower back (IOLANTA observation program). Travmatologiya i ortopediya Rossii. 2018;24(3):55-64. doi: 10.21823/23112905-2018-24-3-55-64 (In Russ.).

7. Flynn T, Fritz J, Whitman J, et al. A clinical prediction rule for classifying patients with low back pain who demonstrate short-term improvement with spinal manipulation. Spine. 2002;27:2835-43. doi: 10.1097/01.BRS.0000035681.33747.8D2

8. Cher D, Polly D, Berven S. Sacroiliac joint pain: burden of disease. Med Devices (Auckl). 2014 Apr 12;7:73-81. doi: 10.2147/MDER.S59437

9. Nagamoto Y, Iwasaki M, Sakaura H, et al. Sacroiliac joint motion in patients with degenerative lumbar spine disorders. J Neurosurg Spine. 2015 Aug;23(2):209-16. doi: 10.3171/2014.12.SPINE14590

10. Adhia DB, Milosavljevic S, Tumilty S, Bussey MD. Innominate movement patterns, rotation trends and range of motion in individuals with low back pain of sacroiliac joint origin. Man Ther. 2016 Feb;21:100-8. doi: 10.1016/j.math.2015.06.004. Epub 2015 Jun 21.

11. Szadek KM, Hoogland PV, Zuurmond WW, et al. Possible nociceptive structures in the sacroiliac joint cartilage: an immunohistochemical study. Clin Anat. 2010 Mar;23(2):192-8. doi: 10.1002/ca.20908

12. Van der Wurff P. Clinical diagnostic tests for the sacroiliac joint: motion and palpation tests. Aust J Physiother. 2006;52(4):308. doi: 10.1016/S0004-9514(06)70017-4

13. Sembrano JN, Polly DW Jr. How often is low back pain not coming from the back? Spine (Phila Pa 1976). 2009 Jan 1;34(1):E27-32. doi: 10.1097/BRS.0b013e31818b8882

14. Ou-Yang DC, York PJ, Kleck CJ, Patel VV. Diagnosis and management of sacroiliac joint dysfunction. J Bone Joint Surg Am. 2017 Dec 6;99(23):2027-36. doi: 10.2106/JBJS.17.00245

15. Cohen SP, Chen Y, Neufeld NJ. Sacroiliac joint pain: a comprehensive review of epidemiology, diagnosis and treatment. Expert Rev Neurother. 2013;13(1):99-116. doi: 10.1586/ern.12.148

16. Schwarzer AC, Aprill CN, Bogduk N. The sacroiliac joint in chronic low back pain. Spine. 1995;20(1):31-7. doi: 10.1097/00007632199501000-00007

17. Zolotovskaya IA, Davydkin IL. Antiresorptivecytokine effects of chondroprotective therapy in patients with lower back pain. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(4):6571 (In Russ.).

18. Gromova OA, Torshin IYu, Lila AM, et al. Chemoreactome analysis of the antithrombotic effects of glucosamine sulfate and nonsteroidal anti-inflammatory drugs. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(1):129-34. doi: 10.14412/1996-70122019-1-129-134 (In Russ.).

19. Gromova OA, Torshin IYu, Lila AM, Gromov AN. Molecular mechanisms of action of glucosamine sulfate in the treatment of degenerative-dystrophic diseases of the joints and spine: results of proteomic analysis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):38-44. doi: 10.14412/2074-27112018-2-38-4415 (In Russ.).

20. Gromova OA, Torshin IYu, Lila AM, et al. Molecular mechanisms of myoprotective action of chondroitin sulfate and glucosamine sulfate in sarcopenia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):117-24. doi: 10.14412/2074-2711-2019-1-117-124 (In Russ.).

21. Zegels B, Crozes P, Uebelhart D, et al. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis Cartilage. 2013;21(1):22-7. doi: 10.1016/j.joca.2012.09.017

22. Alekseeva LI, Anikin SG, Zaitseva EM, et al. Study of the efficacy, tolerability and safety of the drug Hondrogard in patients with osteoarthritis. RMJ. 2013;32:1624-8 (In Russ.).

23. Alekseeva LI. Update clinical guidelines for the treatment of patients with osteoarthritis 2019. RMJ. 2019;27(4):2-6 (In Russ.).

24. Karateev AE, Lila AM. Russian experience with injectable chondroitin sulfate and glucosamine sulfate: a review of clinical trials. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(1):33-40. http://dx.doi.org/10.14412/1996-70122018-1-33-40 (In Russ.).


For citation:


Zolotovskaya I.A., Davydkin I.L. The main clinical and diagnostic characteristics of patients with low back pain and sacroiliac joint diseases (results of the IOLANTA-II study). Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):57-64. (In Russ.) https://doi.org/10.14412/2074-2711-2020-4-57-64

Views: 62


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)